Historical Valuation
Kiora Pharmaceuticals Inc (KPRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.47 is considered Undervalued compared with the five-year average of -1.13. The fair price of Kiora Pharmaceuticals Inc (KPRX) is between 2.83 to 9.90 according to relative valuation methord. Compared to the current price of 2.19 USD , Kiora Pharmaceuticals Inc is Undervalued By 22.63%.
Relative Value
Fair Zone
2.83-9.90
Current Price：2.19
22.63%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Kiora Pharmaceuticals Inc (KPRX) has a current Price-to-Book (P/B) ratio of 0.31. Compared to its 3-year average P/B ratio of 0.44 , the current P/B ratio is approximately -29.53% higher. Relative to its 5-year average P/B ratio of 0.79, the current P/B ratio is about -60.68% higher. Kiora Pharmaceuticals Inc (KPRX) has a Forward Free Cash Flow (FCF) yield of approximately -135.25%. Compared to its 3-year average FCF yield of -76.80%, the current FCF yield is approximately 76.09% lower. Relative to its 5-year average FCF yield of -90.35% , the current FCF yield is about 49.69% lower.
P/B
Median3y
0.44
Median5y
0.79
FCF Yield
Median3y
-76.80
Median5y
-90.35
Competitors Valuation Multiple
AI Analysis for KPRX
The average P/S ratio for KPRX competitors is 12.64, providing a benchmark for relative valuation. Kiora Pharmaceuticals Inc Corp (KPRX.O) exhibits a P/S ratio of 2.47, which is -80.47% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for KPRX
1Y
3Y
5Y
Market capitalization of KPRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of KPRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is KPRX currently overvalued or undervalued?
Kiora Pharmaceuticals Inc (KPRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.47 is considered Undervalued compared with the five-year average of -1.13. The fair price of Kiora Pharmaceuticals Inc (KPRX) is between 2.83 to 9.90 according to relative valuation methord. Compared to the current price of 2.19 USD , Kiora Pharmaceuticals Inc is Undervalued By 22.63% .
What is Kiora Pharmaceuticals Inc (KPRX) fair value?
KPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kiora Pharmaceuticals Inc (KPRX) is between 2.83 to 9.90 according to relative valuation methord.
How does KPRX's valuation metrics compare to the industry average?
The average P/S ratio for KPRX's competitors is 12.64, providing a benchmark for relative valuation. Kiora Pharmaceuticals Inc Corp (KPRX) exhibits a P/S ratio of 2.47, which is -80.47% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Kiora Pharmaceuticals Inc (KPRX) as of Jan 09 2026?
As of Jan 09 2026, Kiora Pharmaceuticals Inc (KPRX) has a P/B ratio of 0.31. This indicates that the market values KPRX at 0.31 times its book value.
What is the current FCF Yield for Kiora Pharmaceuticals Inc (KPRX) as of Jan 09 2026?
As of Jan 09 2026, Kiora Pharmaceuticals Inc (KPRX) has a FCF Yield of -135.25%. This means that for every dollar of Kiora Pharmaceuticals Inc’s market capitalization, the company generates -135.25 cents in free cash flow.
What is the current Forward P/E ratio for Kiora Pharmaceuticals Inc (KPRX) as of Jan 09 2026?
As of Jan 09 2026, Kiora Pharmaceuticals Inc (KPRX) has a Forward P/E ratio of -0.86. This means the market is willing to pay $-0.86 for every dollar of Kiora Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Kiora Pharmaceuticals Inc (KPRX) as of Jan 09 2026?
As of Jan 09 2026, Kiora Pharmaceuticals Inc (KPRX) has a Forward P/S ratio of 2.47. This means the market is valuing KPRX at $2.47 for every dollar of expected revenue over the next 12 months.